Can the testing be performed on dogs that are currently on therapy?

Current therapy will not affect our AI predictions or immunoprofile results. However, reduction of tumor size caused by therapy may increase the likelihood of service failure due to insufficient cells. In the event of service failure, you will not be billed.

Other Questions

Back to Help Center

What does flow cytometry tell me about my patient’s specimen?

ImpriMed’s flow cytometry report provides comprehensive information about the specimen’s immunophenotype. B-cell and T-cell immunophenotypes are useful in determining lymphoma/leukemia subtype and prognosis. In addition, our panel of ten antigens can also be used in the diagnosis of T-zonal lymphoma, acute leukemia, and other diseases. Antigens levels reported are: CD21, CD79a, CD3, CD4, CD8, CD5, CD45, CD34, CD14, and MHC class II. For more information, see: https://pubmed.ncbi.nlm.nih.gov/26953614/

Read More

How does ImpriMed predict drug responses?

Our predictions are made by artificial intelligence (AI) models trained to predict clinical outcomes from patient data inputs. Clinical outcomes collected from oncologists include reports of progressive disease, stable disease, partial response, and complete response. Patient data used as inputs by the AI models include readings from our live-cell drug sensitivity assay, flow cytometry, PARR, and patient information.Models are re-trained periodically to incorporate new data and refine performance.

Read More

What is the successful prediction rate for this test?

Positive predictive values for our AI-based drug response predictions are 80% or higher.

Read More

How should I discard the expired media we still have?

The media and tubes can be decontaminated in or with 10% bleach and discarded as normal.

Read More

What's the breakdown of sensitivity of your PARR for canine B and T cell lymphomas?

PARR Sensitivity for B-Cell is 90.71% and for T-Cell is 85.45%.

Read More